“…On the contrary, a symmetrical treatment pattern (CXL in the present study) also gives a symmetrical treatment effect. In accordance with our previous reports,15 18 this study shows that the increase in corneal densitometry relates to the CXL treatment effect, which is in alignment with recent in vivo confocal microscopy findings, where the phenomenon of light scattering is explained as an ‘indirect sign of CXL-induced stromal collagen compaction and remodeling’ 19. Accordingly, with an asymmetrical treatment pattern as in the present study, an increase in corneal densitometry is seen only where the cornea is crosslinked, but not outside the treatment zone.…”
“…On the contrary, a symmetrical treatment pattern (CXL in the present study) also gives a symmetrical treatment effect. In accordance with our previous reports,15 18 this study shows that the increase in corneal densitometry relates to the CXL treatment effect, which is in alignment with recent in vivo confocal microscopy findings, where the phenomenon of light scattering is explained as an ‘indirect sign of CXL-induced stromal collagen compaction and remodeling’ 19. Accordingly, with an asymmetrical treatment pattern as in the present study, an increase in corneal densitometry is seen only where the cornea is crosslinked, but not outside the treatment zone.…”
“…More importantly, however, increased corneal light scattering on Scheimpflug À0.3 AE 2.7 À0.2 AE 2.5; p = 0.41 0.1 AE 2.3; p = 0.05 À0.7 AE 1.9; p = 0.51 À0.7 AE 1.9; p = 0.36 À0.7 AE 1.9; p = 0.15 Cylinder (D) À3.1 AE 2.1 À3.3 AE 2.1; p = 0.49 À3.1 AE 2.2; p = 0.70 À0.4 AE 0.4; p < 0.01 À0.4 AE 0.4; p < 0.01 À0.5 AE 0.4; p < 0.01 SphEq (D) À1.9 AE 2.8 À1.8 AE 2.5; p = 0.65 À1.4 AE 2.4; p = 0.03 À0.9 AE 1.9; p = 0.09 À0.9 AE 1.9; p = 0.10 À0.9 AE 1.8; p = 0.30 BSCVA (logMar) CXL = conventional corneal crosslinking, CXL ctrl = control subjects to patients treated with CXL, CRXL = corneal crosslinking with mechanical compression of the cornea, CRXL ctrl = control subjects to patients treated with CRXL, SphEq = spherical equivalent, calculated as sphere+cylinder/ 2, BSCVA = best spectacle-corrected visual acuity, logMar = logarithm of the minimum angel of resolution, K max = maximum keratometry value, obtained with the Pentacam â HR, CT min = corneal thickness at the thinnest point, obtained with the Pentacam â HR. photography, previously used as an indicator of the corneal response after CXL by our group (Beckman Rehnman et al 2011), was a consistent finding after both treatments, which indicates that a crosslinking effect did take place in all our subjects, although longitudinal long-term follow up is the only way to quantify this effect. Assessment of the light scattering data, as well as long-term follow up, will be subjects of a future study.…”
Section: Discussionsupporting
confidence: 79%
“…The mechanism underlying the continuing corneal flattening up to 2 years after corneal crosslinking has still not been entirely elucidated (Goldich et al 2012). It has been repeatedly shown that crosslinking halts the progression of keratoconus, and the effects from corneal crosslinking have been convincingly demonstrated in vitro by biochemical (Spoerl et al 2004b;Brummer et al 2011), biomechanical (Wollensak et al 2003b;Knox Cartwright et al 2012;Dias et al 2013), structural (Wollensak et al 2004;Beckman Rehnman et al 2011) and thermomechanical (Spoerl et al 2004a) investigations. Demonstrating an increased biomechanical strength in vivo after CXL treatment using the Ocular Response Analyser (ORA), has been more difficult (Vinciguerra et al 2010;Spoerl et al 2011;Gkika et al 2012;Goldich et al 2012), but it is generally accepted today that CXL acts through an increase in corneal biomechanical strength (Beshtawi et al 2013).…”
ABSTRACT.Purpose: To compare refractive changes after corneal crosslinking with and without mechanical compression of the cornea. Methods: In a prospective, open, randomized case-control study conducted at the Department of Ophthalmology, Ume a University Hospital, Sweden, sixty eyes of 43 patients with progressive keratoconus aged 18-28 years planned for corneal crosslinking and corresponding age-and sex-matched control subjects were included. The patients were randomized to conventional corneal crosslinking (CXL; n = 30) or corneal crosslinking with mechanical compression using a flat rigid contact lens sutured to the cornea during treatment (CRXL; n = 30). Subjective refraction and ETDRS best spectacle-corrected visual acuity (BSCVA), axial length measurement, keratometry and pachymetry were performed before and 1 and 6 months after treatment. Results: The keratoconus patients had poorer BSCVA, higher refractive astigmatism and higher keratometry readings than the control subjects at baseline (p < 0.01). In the CXL group, BSCVA increased from 0.19 AE 0.26 to 0.14 AE 0.18 logMar (p = 0.03), and the spherical equivalent improved from À1.9 AE 2.8 D to À1.4 AE 2.4 D (p = 0.03). Maximum keratometry readings decreased after CXL from 53.1 AE 4.9 D to 52.6 AE 5.2 D (p = 0.02), and the axial length decreased in the CXL group, likely due to post-treatment corneal thinning (p = 0.03). In the CRXL group, all the above variables were unaltered (p > 0.05). Conclusion: At 6 months, the refractive results from CRXL did not surpass those of conventional CXL treatment. Rather, some variables indicated a slightly inferior effect. Possibly, stronger crosslinking would be necessary to stabilize the cornea in the flattened configuration achieved by the rigid contact lens.
“…Variation in corneal surface smoothness and anterior transparency can affect corneal light backscatter, which can be estimated by different approaches, such as optical coherence tomography, Scheimpflug photography, and psychophysical methods (glare testing, adaptive optics visual simulator with diffuser, direct compensation method). 16 , 27 – 29 We found a significant decrease in both peak and average corneal light back-scattering by Scheimpflug imaging in the study group. The decrease in corneal light backscatter was highly correlated with corneal deswelling.…”
BackgroundThe purpose of this study was to evaluate the effect of daily administration of mannitol-enriched sodium hyaluronate ophthalmic solution on the corneal optical properties of subjects wearing low Dk hydrogel (etafilcon A) contact lenses (CLs).MethodsForty-five subjects wearing etafilcon A CLs daily for more than 6 months were recruited into this pilot study. Fifteen of the subjects administered a 10% mannitol-enriched 0.05% sodium hyaluronate solution (study group) once daily and 30 subjects did not administer any ophthalmic solution (control group). The subjects were examined at baseline and one month after recruitment. Changes in central corneal thickness (CCT) and corneal light backscatter were evaluated by Scheimpflug imaging (Pentacam HR). Changes in corneal total high-order aberration, corneal spherical aberration, coma, and trefoil were evaluated using the OPD scan II.ResultsAt one month, corneal light backscatter decreased significantly in the study group (≤18.30 arbitrary units; P<0.05) and this was highly correlated with a decrease in CCT (R=0.81; P=0.04). The decrease in corneal total high-order aberration, spherical aberration, and coma was significantly higher in the study group than in the control group (P<0.05). No changes in corneal light backscatter or CCT were found in the control group during follow-up.ConclusionOnce-daily administration of a mannitol-enriched lubricant ophthalmic solution was effective for improving the corneal optical quality and reducing corneal swelling in subjects wearing low Dk hydrogel (etafilcon A) CLs during one month follow-up.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.